España
India
Italia
대한민국
日本
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Edge
Benzinga Research
Benzinga Pro
Log In
Get Benzinga Pro
Data & APIs
Events
Premarket
Boost
Advertise
Contribute
España
India
Italia
대한민국
日本
Login
Register
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
Earnings
Interviews
Deals
Regulations
Psychedelics
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
Earnings
Interviews
Deals
Regulations
Psychedelics
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Perfect Stock Portfolio
Easy Income Portfolio
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
Comments
Close menu
Loading...
Direxion Daily S&P Biotech Bear 3X Shares
LABD
ARCA
Watchlist
Leave a Comment
Logo brought to you by Benzinga Data
Get Report
Perks
Buy
Compare Brokers
Get Report
Perks
Buy
Compare Brokers
Get Report
Comment
Overview
News
Holdings
Dividends
Short Interest
Latest news for Direxion Daily S&P Biotech Bear 3X Shares (ARCA:LABD)
Direxion Daily S&P Biotech Bear 3X Shares (ARCA: LABD)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Friday, August 30, 2024
EXCLUSIVE: Beyond The Magnificent Seven — Direxion's Egilinsky Reveals Top Sector Picks
Surbhi Jain
Friday, March 24, 2023
These ETFs Let You Maximize Your Exposure To The Biotech Industry's Performance – Whether Positive Or Inverse
Johnny Rice
Friday, March 12, 2021
Let's Take A Look At This Weeks Highest Performing ETFs:
Jon Harris
Thursday, May 14, 2020
3 Bearish ETFs To Profit Bullish Counterparts With Elevated Short Interest
ETF Professor
Monday, February 10, 2020
3 Leveraged Healthcare ETFs Soaring This Month
ETF Professor
Wednesday, September 04, 2019
These Are The Leveraged ETFs At Play When Trade War Worries Strike
Direxion
Wednesday, June 19, 2019
A Beloved Biotech ETF Could Lure Traders Again
ETF Professor
Tuesday, April 09, 2019
Big Moves In Leveraged Biotech ETFs
ETF Professor
Monday, January 14, 2019
This Biotech ETF Is Soaring, But A Bearish Friend Lures Traders
ETF Professor
Tuesday, November 13, 2018
Time Could Be Right For This Biotech ETF
ETF Professor
Wednesday, July 18, 2018
Exploring The Leveraged ETF Trade Heading Into Earnings Season
Benzinga
Monday, June 04, 2018
The 2018 ASCO Meeting Continues Today, Day 4 ...
Benzinga
Friday, May 11, 2018
'From JEF health-care strategiest Jared Holz, on Trump drug speech: "TRUMP SPEECH BENIGN. NON-EVENT. COMMENTS OVERLY VAGUE. SHORTS ARE COVERING. MASSIVE WASTE OF TIME." - CNBC's Meg Tirell Tweets
Benzinga
Pres. Trump Begins Drug Pricing Speech, Watch...
Benzinga
Monday, May 07, 2018
The Week Ahead: Nvidia And Dropbox Earnings, April Retail Sales, Trump Drug Pricing Speech Expected
Benzinga
Tuesday, April 17, 2018
REMINDER: FDA Commissioner Gottlieb To Testif...
Benzinga
Wednesday, March 28, 2018
For Now, Traders Endorse Biotech Rally
Benzinga
Thursday, December 28, 2017
Low Volatility, Bearish Bets Put A Damper On These ETFs This Year
Benzinga
Wednesday, November 29, 2017
Short Interest And Leveraged ETFs
Benzinga
Tuesday, November 14, 2017
Latest Tax Reform Bill From Senate GOP Seeks Repeal Of ACA Individual Mandate
Benzinga
Friday, October 06, 2017
Heaps Of Healthy Health Care ETFs
Benzinga
Tuesday, September 12, 2017
European Society For Medical Oncology (ESMO) ...
Benzinga
Monday, September 11, 2017
European Society For Medical Oncology (ESMO) ...
Benzinga
Saturday, September 09, 2017
What Pharmaceuticals Spend On Lobbying To Influence Trump
Benzinga
Friday, September 01, 2017
Attention Biotech Investors: September Ushers In Another Slew Of PDUFA Catalysts
Benzinga
Thursday, August 31, 2017
A Sign Of Things To Come? Traders Are Betting On More Biotech Mergers
Benzinga
Wednesday, August 16, 2017
Small Biotechs Could Hurt From Scarcity Of Cancer Trial Participants
Benzinga
Wednesday, June 07, 2017
Forget Trump Or Congress, Amazon May Be The Biggest Threat To Drug Pricing
Benzinga
Tuesday, April 25, 2017
Which Leveraged ETFs Will Be Hot This Week?
Benzinga
Thursday, January 12, 2017
The Best BioPharma Plays Amid Uncertainty From Trump Comments
Benzinga
Wednesday, January 11, 2017
All The Markets Trump Moved During His Speech Today
Benzinga
Trump: Drug Industry Is 'Getting Away With Murder'
Benzinga
Thursday, December 22, 2016
Biotech Sector Weak Headed Into Year's End
Benzinga
Tuesday, September 27, 2016
Loving LABU: A Leveraged Biotech ETF On A Torrid Pace
Benzinga
Thursday, August 25, 2016
Biotechs Are Down 17% Since Clinton First Put Industry On Blast Last September
Benzinga
The Active Traders Guide To Hillary Clinton's Rhetoric
Benzinga
Wednesday, August 24, 2016
Biotechs Are Getting Crushed After Clinton And The White House Trash EpiPen Price Hike
Benzinga
Thursday, August 04, 2016
Biotech Rally Stokes Activity In Leveraged ETFs
Benzinga
Wednesday, June 22, 2016
Traders Get It Right (Sort Of) With Leveraged Biotech ETFs
Benzinga
Friday, February 12, 2016
This Little Nugget Of An ETF Is Delivering Astounding Returns
Benzinga
Thursday, February 11, 2016
This Biotech ETF Is Setting A Blistering Pace
Benzinga
Wednesday, January 20, 2016
One Russia ETF To Look At Right Now
Benzinga
Thursday, December 03, 2015
A New Bearish Biotech ETF And A Lazarus Act For A Couple Leveraged Funds
Benzinga
Wednesday, October 28, 2015
Traders Get Adventurous With Leveraged Biotech ETFs
Benzinga
Tuesday, October 06, 2015
Leveraged ETF Rebalancing: It's Not As Bad As It Seems
Benzinga
Friday, October 02, 2015
Breaking Down Biotech ETFs With Leverage
Benzinga
Monday, September 28, 2015
Wild Ride For Leveraged Biotech ETFs Continues
Benzinga
Sunday, September 27, 2015
ETF Outlook: More Biotech Blunders Or A Biotech Bounce?
Benzinga
Wednesday, September 23, 2015
Traders Bet Against Hillary With Leveraged Biotech ETF
Benzinga
Tuesday, September 22, 2015
Investors In This Biotech ETF Must Have Loved Hillary Clinton's Tweet
Benzinga
Show More
